| Name | Title | Contact Details |
|---|
BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020
Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.
Olive View Medical Center is a Sylmar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sheffield Bio-Science is a Norwich, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.